Previous 10 | Next 10 |
First quarter 2021 total revenue of $23.9 million RVL Pharmaceuticals’ Upneeq wins 2021 MedTech Breakthrough Award; gains recognition as outstanding health and medical technology product Upneeq sales trend higher, exhibiting strong sequential growth St...
BRIDGEWATER, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Fi...
BRIDGEWATER, N.J., May 10, 2021 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”), a fully integrated biopharmaceutical company, today announced that its Upneeq ® (oxymetazoline hydroch...
BRIDGEWATER, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 first quarter financial results on ...
Galera Therapeutics (GRTX) +41% on updating data from pancreatic cancer trial.Willamette Valley Vineyards (WVVI) +18%.Nokia Corporation (NOK) +17% on Q1 results.VEREIT (VER) +17% as Realty Income to acquire the company.Enlivex Therapeutics (ENLV) +13%.Pluristem Therapeutics (PS...
Osmotica Pharmaceuticals plc (NASDAQ:OSMT) traded at a new 52-week low today of $3.01. So far today approximately 366,000 shares have been exchanged, as compared to an average 30-day volume of 331,000 shares. Osmotica Pharmaceuticals plc has overhead space with shares priced $3.03, or 7....
Osmotica closed its fourth quarter and full-year 2020 with dropping revenues. It looks as if another clinical trial will be required to refloat arbaclofen ER. Osmotica has signaled its interest in a strategic deal but has been reticent as to the form it might take. Upneeq is O...
Osmotica Pharmaceuticals plc (OSMT) Q4 2020 Results Conference Call March 30, 2021 4:30 PM ET Company Participants Lisa Wilson - Investor Relations Brian Markison - Chairman of the Board and Chief Executive Officer Andrew Einhorn - Chief Financial Officer James Schaub - Executive Vice Preside...
Gainers: [[ELOX]] +19.9%. [[SURF]] +15.0%. [[EVK]] +14.3%. [[EQ]] +10.4%. [[HYFM]] +9.2%.Losers: [[EDAP]] -7.4%. [[IMVT]] -5.3%. [[BYND]] -4.8%. [[CRMD]] -4.8%. [[OSMT]] -3.7%. For further details see: ELOX, SURF, EDAP and IMVT among after-hours movers
Osmotica Pharmaceuticals (OSMT): Q4 GAAP EPS of -$0.88 misses by $0.64.Revenue of $34.53M (-42.4% Y/Y) misses by $1.2M.Strengthened balance sheet by reducing $50 million in debt and increasing cash.Press Release For further details see: Osmotica Pharmaceuticals EPS misses by $0.64, miss...
News, Short Squeeze, Breakout and More Instantly...
Osmotica Pharmaceuticals plc Company Name:
OSMT Stock Symbol:
NASDAQ Market:
Athyrium Provides Capital to Support Long-Term Growth and Exchanges Outstanding Debt into Equity of Certain Reorganized Entities RVL Pharmaceuticals plc Ordinary Shares Expected to be Cancelled in 2024 BRIDGEWATER, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals, I...
Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as They Pursue Strategic Plan RVLP Ordinary Shares Expected t...
BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 inve...